

# *Biopharmaceutics and Clinical Pharmacokinetics*

MILO GIBALDI, PH.D.

*Dean, School of Pharmacy  
Associate Vice President,  
Health Sciences  
University of Washington  
Seattle, Washington*

FOURTH EDITION



LEA & FEBIGER • Philadelphia • London • 1991

**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

Lea & Febiger  
200 Chester Field Parkway  
Malvern, Pennsylvania 19355-9725  
U.S.A.  
(215) 251-2230  
1-800-444-1785

Lea & Febiger (UK) Ltd.  
145a Croydon Road  
Beckenham, Kent BR3 3RB  
U.K.

#### Library of Congress Cataloging-in-Publication Data

Gibaldi, Milo.

Biopharmaceutics and clinical pharmacokinetics / Milo Gibaldi.—  
4th ed.

p. cm.

Includes bibliographical references.

ISBN 0-8121-1346-2

1. Biopharmaceutics. 2. Pharmacokinetics. I. Title

[DNLM: 1. Biopharmaceutics. 2. Pharmacokinetics. QV 38 G437b]

RM301.4.G53 1990

615'.7—dc20

DNLM/DLC

for Library of Congress

90-5614

CIP

*First Edition, 1971*

Reprinted 1973, 1974, 1975

*Second Edition, 1977*

Reprinted 1978, 1979, 1982

*Third Edition, 1984*

Reprinted 1988

*Fourth Edition, 1991*

*First Spanish Edition, 1974*

*First Japanese Edition, 1976*

*Second Japanese Edition, 1981*

*Second Turkish Edition, 1981*

The use of portions of the text of USP XX-NF XV is by permission of the USP Convention. The Convention is not responsible for any inaccuracy of quotation or for false or misleading implication that may arise from separation of excerpts from the original context or by obsolescence resulting from publication of a supplement.

Reprints of chapters may be purchased from Lea & Febiger in quantities of 100 or more.

Copyright © 1991 by Lea & Febiger. Copyright under the International Copyright Union. All Rights Reserved. This book is protected by copyright. No part of it may be reproduced in any manner or by any means without written permission from the publisher.

# Contents

1.	Introduction to Pharmacokinetics .....	1
2.	Compartmental and Noncompartmental Pharmacokinetics .....	14
3.	Gastrointestinal Absorption— Biologic Considerations .....	24
4.	Gastrointestinal Absorption— Physicochemical Considerations .....	40
5.	Gastrointestinal Absorption— Role of the Dosage Form.....	61
6.	Nonoral Medication.....	80
7.	Prolonged-Release Medication.....	124
8.	Bioavailability.....	146
9.	Drug Concentration and Clinical Response .....	176
10.	Drug Disposition—Distribution .....	187
11.	Drug Disposition—Elimination.....	203

12.	Pharmacokinetic Variability— Body Weight, Age, Sex, and Genetic Factors.....	234
13.	Pharmacokinetic Variability—Disease.....	272
14.	Pharmacokinetic Variability—Drug Interactions.....	305
15.	Individualization and Optimization of Drug Dosing Regimens.....	344
	Appendix I. Estimation of Area Under the Curve.....	377
	Appendix II. Method of Superposition.....	379
	Index.....	381

# Introduction to Pharmacokinetics

---

Advancements in biopharmaceutics have come about largely through the development and application of pharmacokinetics. Pharmacokinetics is the study and characterization of the time course of drug absorption, distribution, metabolism, and excretion, and the relationship of these processes to the intensity and time course of therapeutic and toxicologic effects of drugs. Pharmacokinetics is used in the clinical setting to enhance the safe and effective therapeutic management of the individual patient. This application has been termed *clinical pharmacokinetics*.

## DISTRIBUTION AND ELIMINATION

The transfer of a drug from its absorption site to the blood, and the various steps involved in the distribution and elimination of the drug in the body, are shown in schematic form in Figure 1-1. In the blood, the drug distributes rapidly between the plasma and erythrocytes (red blood cells). Rapid distribution of drug also occurs between the plasma proteins (usually albumin but sometimes  $\alpha_1$ -acid glycoproteins and occasionally globulin) and plasma water. Since most drugs are relatively small molecules they readily cross the blood capillaries and reach the extracellular fluids of almost every organ in the body. Most drugs are also sufficiently lipid soluble to cross cell membranes and distribute in the intracellular fluids of various tissues. Throughout the body there is a distribution of drug between body water and proteins or other macromolecules that are dispersed in the body fluids or are components of the cells.

The body can be envisioned as a collection of separate compartments, each containing some fraction of the administered dose. The transfer of drug from one compartment to another is associated with

a rate constant ( $k$ ). The magnitude of the rate constant determines how fast the transfer occurs.

The transfer of drug from blood to extravascular fluids (i.e., extracellular and intracellular water) and tissues is called *distribution*. Drug distribution is usually a rapid and reversible process. Fairly quickly after intravenous (iv) injection, drug in the plasma exists in a distribution equilibrium with drug in the erythrocytes, in other body fluids, and in tissues. As a consequence of this dynamic equilibrium, changes in the concentration of drug in the plasma are indicative of changes in drug level in other tissues including sites of pharmacologic effect (bioreceptors).

The transfer of drug from the blood to the urine or other excretory compartments (i.e., bile, saliva, and milk), and the enzymatic or biochemical transformation (*metabolism*) of drug in the tissues or plasma to metabolic products, are usually irreversible processes. The net result of these irreversible steps, depicted in Figure 1-1, is called *drug elimination*. Elimination processes are responsible for the physical or biochemical removal of drug from the body.

The moment a drug reaches the bloodstream, it is subject to both distribution and elimination. The rate constants associated with distribution, however, are usually much larger than those related to drug elimination. Accordingly, drug distribution throughout the body is usually complete while most of the dose is still in the body. In fact, some drugs attain distribution equilibrium before virtually any of the dose is eliminated. In such cases, the body appears to have the characteristics of a single compartment.

This simplification, however, may not be applied to all drugs. For most drugs, concentrations in plasma measured shortly after iv injection reveal a

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.